Author Archives: Kara Elam

Promising Target for Huntington’s Disease Found

In a recent study, the modification of a specific component of the huntingtin protein reduced neurodegenerative symptoms in an animal model’s brain and offered hope for future therapies that could effectively treat Huntington’s disease in humans. The study, “Serine 421 regulates mutant huntingtin toxicity and clearance in mice,” was published in the…

Huntington’s Research Likely to Benefit from Device Aiding Studies of Neurological Diseases in a Living Animal

Researchers from the École Polytechnique Fédérale de Lausanne (EPFL), Switzerland, led by Dr. Matteo Cornaglia, PhD, have developed a new experimental device that can assist scientists in the analysis of molecular pathway studies related to complex human dysfunctions, such as neurodegenerative diseases like Huntington’s (HD). The device is intended for use with the…

Huntington’s Disease and Its Troubling Weight Loss Studied

A recent study explored the association between gastric mucosa (mucus lining) abnormalities in Huntington’s Disease (HD) and mechanisms in the increased weight loss experienced by HD patients.  The study, entitled, “Characterization of Gastric Mucosa Biopsies Reveals Alterations in Huntington’s Disease,” was published in the journal…

Reata Announces Enrollment of First Patient in Phase 2 Study of RTA 408 for the Treatment of Friedreich’s Ataxia

the powerhouse of the cell Irving, Texas based Reata Pharmaceuticals, whose mission is to translate innovative research into breakthrough medicines for difficult-to-treat diseases that have significant unmet needs, recently announced the enrollment of their first patient into MOXIe, their Phase 2 clinical study examining the safety, tolerability,…